Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAURUS MRD monitoring study in newly diagnosed transplant-eligible multiple myeloma
NL-OMON58820Phase 2Active, not recruiting
- Sponsor
- European Myeloma Network B.V.
- Start
- Apr 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of talquetamab and ramalimab in multiple myeloma (MM) (4 cohorts), sponsored by European Myeloma Network B.V. Started Apr 2024; status: active, not recruiting.
02
Drugs
talquetamabramalimab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON58820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58820.